NCT01609933View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 18, 2012

Primary Completion Date

May 3, 2017

Study Completion Date

May 3, 2017

Conditions
Chronic Hepatitis C
Interventions
DRUG

ABT-450/r

ABT-450 (tablets) dosed with ritonavir (capsules or tablets)

DRUG

ABT-267

ABT-267 (tablets)

DRUG

pegylated interferon alpha-2a (pegIFN)

pegIFN alpha-2a (syringe)

DRUG

Ribavirin (RBV)

Ribavirin (tablets)

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01609933 - A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study | Biotech Hunter | Biotech Hunter